LONDON (Thomson Financial) - Specialist British drug delivery company Skye
pharma Plc. said it expects its bond proposals, placing and open offer to be finalised on Sept 25.
It added it expects the consolidated new shares to be issued pursuant to the placing and open offer to be admitted to the Official List and to commence trading on the London Stock Exchange on Sept. 26 and the bond proposals to be implemented on or around Oct. 1.
On Sept. 1, SkyePharma had said in a statement it would sell 1.4 billion new shares at 1.5 pence in an underwritten placing and open offer.
It had also stated 70 percent of the holders of its 2024 convertible bond and 100 percent of the holders of its 2025 convertible had agreed to proposed changes to the conversion price and dates for put options on the two convertibles.
COPYRIGHT Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.